Cargando…

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer

Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several molecular alterations that confer resistance to standard chemotherapy and targeted agents. Mechanisms of resistance have been identified at multip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martini, Giulia, Dienstmann, Rodrigo, Ros, Javier, Baraibar, Iosune, Cuadra-Urteaga, Jose Luis, Salva, Francesc, Ciardiello, Davide, Mulet, Nuria, Argiles, Guillem, Tabernero, Josep, Elez, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383645/ https://www.ncbi.nlm.nih.gov/pubmed/32782486 http://dx.doi.org/10.1177/1758835920936089

Ejemplares similares

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
por: Baraibar, Iosune, et al.
Publicado: (2021)

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy
por: Élez, Elena, et al.
Publicado: (2022)

Liver transplantation in metastatic colorectal cancer: are we ready for it?
por: Ros, Javier, et al.
Publicado: (2023)

Correction To: Liver transplantation in metastatic colorectal cancer: are we ready for it?
por: Ros, Javier, et al.
Publicado: (2023)

Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
por: Ros, Javier, et al.
Publicado: (2023)

The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey
por: Rodriguez Castells, Marta, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
por: Ros, Javier, et al.
Publicado: (2023)

Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications
por: Saoudi González, Nadia, et al.
Publicado: (2023)

Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer
por: Martini, G., et al.
Publicado: (2023)

Sex and gender perspectives in colorectal cancer
por: Baraibar, I., et al.
Publicado: (2023)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Impact of the COVID-19 pandemic in the early-onset colorectal cancer
por: Baraibar, Iosune, et al.
Publicado: (2023)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
por: Serna, Garazi, et al.
Publicado: (2019)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941
por: Ciardiello, Davide, et al.
Publicado: (2022)

Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network
por: Mulet Margalef, Núria, et al.
Publicado: (2023)

Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights
por: Dienstmann, Rodrigo, et al.
Publicado: (2017)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

New clinical trial designs in the era of precision medicine
por: Garralda, Elena, et al.
Publicado: (2019)

Unveiling changes in the landscape of patient populations in cancer early drug development
por: Hierro, Cinta, et al.
Publicado: (2016)

Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer
por: Argiles, Guillem
Publicado: (2018)

Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
por: Saoudi González, Nadia, et al.
Publicado: (2022)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2022)

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017)

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
por: Tabernero, Josep, et al.
Publicado: (2020)

Human T Lymphotropic virus-1 associated gastrointestinal histoplasmosis in Peru
por: Canelo-Aybar, Carlos, et al.
Publicado: (2011)

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
por: Román, Marta, et al.
Publicado: (2018)

332P Impact of the COVID-19 pandemic in the early-onset colorectal cancer (EOCRC)
por: Baraibar Argota, I., et al.
Publicado: (2022)

Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report
por: Baraibar, Iosune, et al.
Publicado: (2017)

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
por: Elez, E, et al.
Publicado: (2016)

Hashimoto's encephalopathy presenting with neurocognitive symptoms: a case report
por: Canelo-Aybar, Carlos, et al.
Publicado: (2010)

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
por: Serna, G., et al.
Publicado: (2020)

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017)

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
por: Van Cutsem, Eric, et al.
Publicado: (2019)

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
por: Tabernero, Josep, et al.
Publicado: (2021)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qcc7svarb7m4jhght88gvsfcfm